Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$136.16 USD
+1.08 (0.80%)
Updated Jun 26, 2024 02:36 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 261 - 280 ( 309 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Transferring Coverage and Placing Under Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
1Q13 - KINECT and KINECT-II Data Releases in 2H13 Are The Focus
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Former Announcement of the Start of Elagolix in UF Phase IIb Study
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J